157 related articles for article (PubMed ID: 15771766)
21. Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.
Hlavaty T; Pierik M; Henckaerts L; Ferrante M; Joossens S; van Schuerbeek N; Noman M; Rutgeerts P; Vermeire S
Aliment Pharmacol Ther; 2005 Oct; 22(7):613-26. PubMed ID: 16181301
[TBL] [Abstract][Full Text] [Related]
22. Prediction of response to infliximab in Crohn's disease.
Chaudhary R; Ghosh S
Dig Liver Dis; 2005 Aug; 37(8):559-63. PubMed ID: 15893967
[No Abstract] [Full Text] [Related]
23. Crohn's-associated chronic recurrent multifocal osteomyelitis responsive to infliximab.
Carpenter E; Jackson MA; Friesen CA; Scarbrough M; Roberts CC
J Pediatr; 2004 Apr; 144(4):541-4. PubMed ID: 15069408
[TBL] [Abstract][Full Text] [Related]
24. Infliximab therapy in Crohn's disease: a pragmatic approach?
Kevans D; Keegan D; Mulcahy HE; O'Donoghue DP
Aliment Pharmacol Ther; 2006 Jul; 24(2):351-9. PubMed ID: 16842462
[TBL] [Abstract][Full Text] [Related]
25. The real cost of pediatric Crohn's disease: the role of infliximab in the treatment of pediatric IBD.
Kay M; Wyllie R
Am J Gastroenterol; 2003 Apr; 98(4):717-20. PubMed ID: 12738445
[No Abstract] [Full Text] [Related]
26. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. CON: "lifetime use" is an awfully long time.
Loftus EV
Am J Gastroenterol; 2005 Jul; 100(7):1435-8. PubMed ID: 15984960
[No Abstract] [Full Text] [Related]
27. Guidelines for treatment with infliximab for Crohn's disease.
Hommes DW; Oldenburg B; van Bodegraven AA; van Hogezand RA; de Jong DJ; Romberg-Camps MJ; van der Woude J; Dijkstra G;
Neth J Med; 2006; 64(7):219-29. PubMed ID: 16929083
[TBL] [Abstract][Full Text] [Related]
28. Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.
Lichtenstein GR
Am J Gastroenterol; 2005 Jul; 100(7):1433-5. PubMed ID: 15984959
[No Abstract] [Full Text] [Related]
29. Therapeutic efficacy of infliximab on patients with short duration of Crohn's disease: a Japanese multicenter survey.
Matsumoto T; Iida M; Motoya S; Haruma K; Suzuki Y; Kobayashi K; Ito H; Miyata M; Kusunoki M; Chiba T; Yamamoto S; Hibi T
Dis Colon Rectum; 2008 Jun; 51(6):916-23. PubMed ID: 18322754
[TBL] [Abstract][Full Text] [Related]
30. [Pneumocystis pneumonia during infliximab treatment for active Crohn's colitis].
Minnee RC; Stokkers P; Riemens SC; Hommes DW
Ned Tijdschr Geneeskd; 2005 Oct; 149(41):2290-5. PubMed ID: 16240855
[TBL] [Abstract][Full Text] [Related]
31. Severe lower gastrointestinal bleeding in Crohn's disease: successful control with infliximab.
Belaiche J; Louis E
Am J Gastroenterol; 2002 Dec; 97(12):3210-1. PubMed ID: 12492221
[No Abstract] [Full Text] [Related]
32. The impact of major depressive disorder on the short- and long-term outcome of Crohn's disease treatment with infliximab.
Persoons P; Vermeire S; Demyttenaere K; Fischler B; Vandenberghe J; Van Oudenhove L; Pierik M; Hlavaty T; Van Assche G; Noman M; Rutgeerts P
Aliment Pharmacol Ther; 2005 Jul; 22(2):101-10. PubMed ID: 16011668
[TBL] [Abstract][Full Text] [Related]
33. Autoantibody profile during short-term infliximab treatment for Crohn's disease: a prospective cohort study.
Atzeni F; Ardizzone S; Sarzi-Puttini P; Colombo E; Maconi G; De Portu S; Carrabba M; Bianchi Porro G
Aliment Pharmacol Ther; 2005 Sep; 22(5):453-61. PubMed ID: 16128684
[TBL] [Abstract][Full Text] [Related]
34. Acute idiopathic pancreatitis complicating active Crohn's disease: favorable response to infliximab treatment.
Triantafillidis JK; Cheracakis P; Hereti IA; Argyros N; Karra E
Am J Gastroenterol; 2000 Nov; 95(11):3334-6. PubMed ID: 11095387
[No Abstract] [Full Text] [Related]
35. The frequency of sister chromatid exchanges in patients with Crohn's disease and the effect of therapy with "anti-tumor necrosis factor" on this frequency.
Danalioglu A
Hepatogastroenterology; 2009; 56(91-92):729-33. PubMed ID: 19621692
[TBL] [Abstract][Full Text] [Related]
36. Infliximab in the treatment of Crohn's disease: predictors of response in an Italian multicentric open study.
Orlando A; Colombo E; Kohn A; Biancone L; Rizzello F; Viscido A; Sostegni R; Benazzato L; Castiglione F; Papi C; Meucci G; Riegler G; Mocciaro F; Cassinotti A; Cosintino R; Geremia A; Morselli C; Angelucci E; Lavagna A; Rispo A; Bossa F; Scimeca D; Cottone M;
Dig Liver Dis; 2005 Aug; 37(8):577-83. PubMed ID: 15886081
[TBL] [Abstract][Full Text] [Related]
37. Long-term partial remission of autoimmune thrombocytopenia in a patient treated with the anti-tumor necrosis factor-alpha antibody infliximab for refractory fistulizing Crohn's disease.
de Rossi TM; Krauss N; Voll RE; Nägel A; Weidenhiller M; Konturek PC; Hahn EG; Raithel M
Digestion; 2008; 78(4):195-200. PubMed ID: 19122456
[TBL] [Abstract][Full Text] [Related]
38. Fistulating anal Crohn's disease: results of combined surgical and infliximab treatment.
Hyder SA; Travis SP; Jewell DP; McC Mortensen NJ; George BD
Dis Colon Rectum; 2006 Dec; 49(12):1837-41. PubMed ID: 17041753
[TBL] [Abstract][Full Text] [Related]
39. Vulvitis granulomatosa, Melkersson-Rosenthal syndrome, and Crohn's disease: dramatic response to infliximab therapy.
Wickramasinghe N; Gunasekara CN; Fernando WS; Hewavisenthi J; de Silva HJ
Int J Dermatol; 2012 Aug; 51(8):966-8. PubMed ID: 22788815
[No Abstract] [Full Text] [Related]
40. The effect of anti-TNF-alpha therapy on spinal bone mineral density in patients with Crohn's disease.
Pazianas M; Rhim AD; Weinberg AM; Su C; Lichtenstein GR
Ann N Y Acad Sci; 2006 Apr; 1068():543-56. PubMed ID: 16831950
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
